StreetInsider.com News Articles

Context Therapeutics doses first patient in CT-202 Phase 1 trial

Wed, 09 Sep 2026 07:30:15 -0400

Context Therapeutics Inc. (Nasdaq: CNTX) announced that the first patient has been dosed in a Phase 1 clinical trial of CT-202, a Nectin-4 x CD3 T cell engaging bispecific antibody, according to a company statement.

The open-label, dose escalation trial (NCT07545122) is evaluating CT-202 as a monotherapy in patients with Nectin-4-expressing recurrent, unresectable, or metastatic refractory or resistant urothelial, colorectal, and triple-negative breast cancers. The study is designed to assess safety, tolerability, pharmacokinetics, and preliminary antitumor activity.

CT-202 targets Nectin-4, a cell surface protein that is overexpressed in several solid tumor types, including bladder, colorectal, lung, and breast cancers. The compound is

Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202

Wed, 09 Sep 2026 07:30:00 -0400

CT-202 is a Nectin-4 x CD3 T cell engaging bispecific antibody

Phase 1 trial is evaluating CT-202 as a monotherapy treatment in patients with urothelial, colorectal, and triple-negative breast cancers

PHILADELPHIA, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced that the first patient has been dosed in the Phase 1 clinical trial of CT-202, a Nectin-4 x CD3 TCE bispecific antibody.

“Dosing the first patient in the Phase

Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202

Wed, 09 Sep 2026 07:30:00 -0400

CT-202 is a Nectin-4 x CD3 T cell engaging bispecific antibody

Phase 1 trial is evaluating CT-202 as a monotherapy treatment in patients with urothelial, colorectal, and triple-negative breast cancers

“Dosing the first patient in the Phase

Form SCHEDULE 13G/A Context Therapeutics Filed by: MPM BioImpact LLC

Fri, 14 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260814/26930113.html

Form SCHEDULE 13G/A Context Therapeutics Filed by: MPM BioImpact LLC

Fri, 14 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260814/26930113.html

Form SCHEDULE 13G/A Context Therapeutics Filed by: Blue Owl Capital Holdings LP

Wed, 12 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260812/26913473.html

Form SCHEDULE 13G/A Context Therapeutics Filed by: Blue Owl Capital Holdings LP

Wed, 12 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260812/26913473.html

Context Therapeutics Inc. (CNTX) Misses Q2 EPS by 6c

Thu, 06 Aug 2026 02:45:32 -0400

Context Therapeutics Inc. (NASDAQ: CNTX) reported Q2 EPS of ($0.15), $0.06 worse than the analyst estimate of ($0.09).

For earnings history and earnings-related data on Context Therapeutics Inc. (CNTX) click here.

Form 8-K Context Therapeutics For: Aug 05

Wed, 05 Aug 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260805/26874627.html

Form 8-K Context Therapeutics For: Aug 05

Wed, 05 Aug 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260805/26874627.html

Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress

Wed, 05 Aug 2026 16:14:00 -0400

Prioritization of CTIM-76 and CT-202 clinical programs, with initial clinical readouts expected beginning in Q2 2027